Gene · 580
Papers4,139
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
361 to 380 of 4,139
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| FIGNL1 AAA+ ATPase remodels RAD51 and DMC1 filaments in pre-meiotic DNA replication and meiotic recombination. | Nat Commun | 2023 | 37891173 | PubTator, text mining | PubMed |
| Deubiquitylating Enzymes in Cancer and Immunity. | Adv Sci (Weinh) | 2023 | 37888853 | PubTator, text mining | PubMed |
| Bioinformatic Analysis of Recurrent Genomic Alterations and Corresponding Pathway Alterations in Ewing Sarcoma. | J Pers Med | 2023 | 37888109 | PubTator, text mining | PubMed |
| Identification of BRCC3 and BRCA1 as Regulators of TAZ Stability and Activity. | Cells | 2023 | 37887275 | PubTator, text mining | PubMed |
| Global epidemiology of breast cancer based on risk factors: a systematic review. | Front Oncol | 2023 | 37886170 | PubTator, text mining | PubMed |
| Transcriptomic analysis identifies lactoferrin-induced quiescent circuits in neonatal macrophages. | Front Immunol | 2023 | 37868991 | PubTator, text mining | PubMed |
| Mutational topography reflects clinical neuroblastoma heterogeneity. | Cell Genom | 2023 | 37868040 | PubTator, text mining | PubMed |
| TRIM21 mediates the synergistic effect of Olaparib and Sorafenib by degrading BRCA1 through ubiquitination in TNBC. | NPJ Breast Cancer | 2023 | 37864041 | PubTator, text mining | PubMed |
| Similarities and differences in gene expression profiles of BRCA1 methylated and mutated epithelial ovarian cancers. | Front Oncol | 2023 | 37854675 | PubTator, text mining | PubMed |
| The Largest Chinese Cohort Study Indicates Homologous Recombination Pathway Gene Mutations as Another Major Genetic Risk Factor for Colorectal Cancer with Heterogeneous Clinical Phenotypes. | Research (Wash D C) | 2023 | 37854294 | PubTator, text mining | PubMed |
| Interaction, immune infiltration characteristics and prognostic modeling of efferocytosis-related subtypes in glioblastoma. | BMC Med Genomics | 2023 | 37853449 | PubTator, text mining | PubMed |
| Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study. | ESMO Open | 2023 | 37852034 | PubTator, text mining | PubMed |
| Two bullets in the gun: combining immunotherapy with chemotherapy to defeat neuroblastoma by targeting adrenergic-mesenchymal plasticity. | Front Immunol | 2023 | 37849756 | PubTator, text mining | PubMed |
| The clinical challenges of homologous recombination proficiency in ovarian cancer: from intrinsic resistance to new treatment opportunities. | Cancer Drug Resist | 2023 | 37842243 | PubTator, text mining | PubMed |
| Primary and acquired resistance to first-line therapy for clear cell renal cell carcinoma. | Cancer Drug Resist | 2023 | 37842234 | PubTator, text mining | PubMed |
Case Report: Complete pathological remission of human chorionic gonadotrophin-producing gallbladder carcinoma with multiple liver metastases after treatment with chemotherapy plus an immune checkpoint inhibitor. | Front Immunol | 2023 | 37841278 | PubTator, text mining | PubMed |
| Next-generation sequencing in dermatology. | Front Med (Lausanne) | 2023 | 37841001 | PubTator, text mining | PubMed |
| New Facets of DNA Double Strand Break Repair: Radiation Dose as Key Determinant of HR versus c-NHEJ Engagement. | Int J Mol Sci | 2023 | 37834403 | PubTator, text mining | PubMed |
Recommendations for breast cancer screening in Brazil, from the Brazilian College of Radiology and Diagnostic Imaging, the Brazilian Society of Mastology, and the Brazilian Federation of Gynecology and Obstetrics Associations. | Radiol Bras | 2023 | 37829583 | PubTator, text mining | PubMed |
| [BRCA-like breast cancer patients benefit from cisplatin plus veliparib-results from the S1416 phase II study]. | Strahlenther Onkol | 2023 | 37823898 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/580/papers?page=19